LILLY's PROZAC FOR BULIMIA GAINS UNANIMOUS RECOMMENDATION FROM FDA PSYCHOPHARM ADVISORY CMTE.; ISSUES OF DOSE LEVELS AND TREATMENT LENGTH REMAIN
Executive Summary
Lilly's Prozac should be approved for treatment of bulimia at 60 mg/day based on data from three clinical trials, FDA's Psychopharmacologic Drugs Advisory Committee unanimously agreed at its April 26 meeting.